DR 30318
Alternative Names: DR-30318Latest Information Update: 23 Jun 2022
At a glance
- Originator Zhejiang Doer Biologics
- Class Antineoplastics; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins; Single-domain antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 May 2022 Preclinical trials in Solid tumours in China (Parenteral) (Zhejiang Doer Biologics pipeline, May 2022)